Home >> Signaling Pathways >> MAPK Signaling >> Raf

Raf

Raf is a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.

Products for  Raf

  1. Cat.No. Product Name Information
  2. GC32797 AD80 AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity. AD80  Chemical Structure
  3. GC15055 AZ 628

    Raf kinases,potent and ATP-competitive

    AZ 628  Chemical Structure
  4. GC19479 AZ304

    A dual inhibitor

    AZ304  Chemical Structure
  5. GC10534 B-Raf IN 1 B-Raf inhibitor B-Raf IN 1  Chemical Structure
  6. GC65978 B-Raf IN 10 B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity. B-Raf IN 10  Chemical Structure
  7. GC67800 B-Raf IN 11 B-Raf IN 11  Chemical Structure
  8. GC64550 B-Raf IN 2 B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer. B-Raf IN 2  Chemical Structure
  9. GC12151 B-Raf inhibitor B-Raf inhibitor  Chemical Structure
  10. GC11599 B-Raf inhibitor 1 B-Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. B-Raf inhibitor 1  Chemical Structure
  11. GC14907 B-Raf inhibitor 1 dihydrochloride B-B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. B-Raf inhibitor 1 dihydrochloride  Chemical Structure
  12. GC32950 Belvarafenib An inhibitor of B-RAF and C-RAF Belvarafenib  Chemical Structure
  13. GC35488 Belvarafenib TFA Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. Belvarafenib TFA  Chemical Structure
  14. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283  Chemical Structure
  15. GC18178 BI-882370 A RAF inhibitor BI-882370  Chemical Structure
  16. GC13468 BI-D1870 P90 RSK inhibitor,ATP-competitive and cell-permeable BI-D1870  Chemical Structure
  17. GC11497 BIRB 796 (Doramapimod) BIRB 796 (Doramapimod) (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. BIRB 796 (Doramapimod)  Chemical Structure
  18. GC12482 BRAF inhibitor BRAF inhibitor  Chemical Structure
  19. GC19091 CCT196969 CCT196969, a pan-Raf inhibitor, inhibits B-Raf with an IC50 of 0.1 uM. CCT196969  Chemical Structure
  20. GC16845 CEP-32496 CEP-32496 (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of BRAFV600E with a Kd of 14 nM. CEP-32496  Chemical Structure
  21. GC17860 CEP-32496 hydrochloride A potent inhibitor of B-Raf CEP-32496 hydrochloride  Chemical Structure
  22. GC15187 Dabrafenib (GSK2118436) Dabrafenib (GSK2118436) (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively. Dabrafenib (GSK2118436)  Chemical Structure
  23. GC12486 Dabrafenib Mesylate (GSK-2118436) A Raf kinase inhibitor Dabrafenib Mesylate (GSK-2118436)  Chemical Structure
  24. GC33206 ERK-IN-1 ERK-IN-1 (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. ERK-IN-1 hydrochloride can also inhibit RAF. ERK-IN-1  Chemical Structure
  25. GC67964 Exarafenib Exarafenib  Chemical Structure
  26. GC10505 GDC-0879 B-Raf inhibitor,potent and selective GDC-0879  Chemical Structure
  27. GC65949 GNE-9815 GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers. GNE-9815  Chemical Structure
  28. GC11685 GW5074 C-Raf inhibitor,potent and selective GW5074  Chemical Structure
  29. GC36223 HG6-64-1 HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. HG6-64-1  Chemical Structure
  30. GC15924 L-779,450 Raf kinase inhibitor L-779,450  Chemical Structure
  31. GC16576 LGX818 LGX818 (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM). LGX818  Chemical Structure
  32. GC19507 LUT-014

    LUT014 is a topical B-Raf Inhibitor

    LUT-014  Chemical Structure
  33. GC19228 LXH254 LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254  Chemical Structure
  34. GC13980 LY3009120

    LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.

    LY3009120  Chemical Structure
  35. GC15296 ML 786 dihydrochloride Raf kinase inhibitor ML 786 dihydrochloride  Chemical Structure
  36. GC11649 MLN 2480 An oral pan-Raf kinase inhibitor MLN 2480  Chemical Structure
  37. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  38. GC15821 PF-04880594 RAF inhibitor PF-04880594  Chemical Structure
  39. GC14732 PLX-4720 An orally-available inhibitor of the B-raf mutant B-RafV600E PLX-4720  Chemical Structure
  40. GC62206 PLX-4720-d7 PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf. PLX-4720-d7  Chemical Structure
  41. GC10324 PLX7904 paradox-breaker RAF inhibitor, potent and selective PLX7904  Chemical Structure
  42. GC64828 PLX7922 PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines. PLX7922  Chemical Structure
  43. GC32686 PLX8394 PLX8394  Chemical Structure
  44. GC65479 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity. PROTAC B-Raf degrader 1  Chemical Structure
  45. GC61485 Raf inhibitor 2 Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. Raf inhibitor 2  Chemical Structure
  46. GC37068 RAF mutant-IN-1 RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively. RAF mutant-IN-1  Chemical Structure
  47. GC15818 RAF265 Multiple intracellular kinases inhibitor RAF265  Chemical Structure
  48. GC19307 RAF709 RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively. RAF709  Chemical Structure
  49. GC62504 RAS/RAS-RAF-IN-1 RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity. RAS/RAS-RAF-IN-1  Chemical Structure
  50. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride  Chemical Structure
  51. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate  Chemical Structure
  52. GC62448 Rineterkib hydrochloride Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. Rineterkib hydrochloride  Chemical Structure
  53. GC12406 RO5126766(CH5126766) RO5126766(CH5126766) (CH5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively). RO5126766(CH5126766)  Chemical Structure
  54. GC62269 RRD-251 RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities. RRD-251  Chemical Structure
  55. GC11890 SB590885 Potent B-Raf inhibitor SB590885  Chemical Structure
  56. GC17369 Sorafenib

    Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC50 values of 6 nM and 22 nM, respectively.

    Sorafenib  Chemical Structure
  57. GC37664 Sorafenib (D3) An internal standard for the quantification of sorafenib Sorafenib (D3)  Chemical Structure
  58. GC37665 Sorafenib (D4) Sorafenib (D4) (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. Sorafenib (D4)  Chemical Structure
  59. GC49700 Takeda-6d Takeda-6d  Chemical Structure
  60. GC68350 Tinlorafenib Tinlorafenib  Chemical Structure
  61. GC13412 Vemurafenib (PLX4032, RG7204)

    An inhibitor of mutant V600E and wild type B-Raf

    Vemurafenib (PLX4032, RG7204)  Chemical Structure
  62. GC13286 ZM336372 C-Raf inhibitor, potent and selective ZM336372  Chemical Structure

61 Item(s)

per page

Set Descending Direction